Regeneron Pharmaceuticals’ multiple myeloma drug linvoseltamab has clinical trial results showing complete responses in 90% of patients who have light chain amyloidosis, a rare blood disease. The preliminary data were presented during the annual meeting of the American Society of Clinical Oncology.
The post Regeneron Cancer Drug Shows New Promise in a Rare Disease… and Maybe More appeared first on MedCity News.
